Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows new medication effectively treats underlying cause of cystic fibrosis

03.11.2011
Final stage clinical trial shows significantly improved lung function in subset of CF patients

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation," led by Bonnie W. Ramsey, MD of Seattle Children's Research Institute and the University of Washington, were published today in the New England Journal of Medicine.

Ivacaftor, also known as VX-770, was developed by Vertex Pharmaceuticals with financial support from the Cystic Fibrosis Foundation. The oral medicine targets the defective protein produced by the gene mutation called G551D that causes CF. Researchers found that patients carrying G551D – approximately four per cent of all CF patients – who were treated with VX-770 showed a 17 per cent relative improvement in lung function that was sustained over the course of 48 weeks.

Additionally, patients with G551D treated with VX-770 showed improvements in other areas critically important to the health of people with CF. Study participants experienced significant reductions in sweat chloride levels indicating an improvement in the body's ability to carry salt in and out of cells – a process which when defective leads to CF. They also experienced decreased respiratory distress symptoms and improved weight gain. Those who received VX-770 gained on average seven pounds compared to those in the placebo group who gained approximately one pound. This is significant because many people with CF have difficulty gaining and maintaining weight due to reduced lung function and chronic infection.

"Our study shows that we are now able to improve the quality of life for cystic fibrosis patients with the G551D mutation with the administration of VX-770," said Dr. Ramsey, director of the Center for Clinical and Translational Research at Seattle Children's Research Institute and endowed chair in Cystic Fibrosis (CF) in the Department of Pediatrics at the University of Washington School of Medicine.

Dr. Ramsey and co-investigators evaluated lung function in patients 12 years or older who carry at least one copy of the G551D mutation. The study included 161 patients at multiple healthcare centers who received at least one dose of VX-770 or placebo. The study is the third and final in a series designed to assess VX-770's effectiveness and safety before it is approved for public use.

Approximately 30,000 children and adults in the United States and 70,000 people worldwide have CF. The disease is caused by a defective gene that affects many parts of the body, but is especially harmful to the lungs and pancreas. The gene mutation causes very thick, sticky mucus to clog the lungs and often cause life-threatening infections. In the 1950s, few children with CF lived beyond age five. Today, advances in research and medical treatments have made it possible for people with CF to live well into their 30s, 40s and beyond.

Co-investigators of this study in the Washington region are: Moira Aitken, MD, professor of medicine in the Division of Pulmonary and Critical Care Medicine at the University of Washington Medical Center and Ronald Gibson, MD, PhD, director of the Cystic Fibrosis Clinical Center at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine.

Other co-investigators of the study include: Jane Davies, MD, MB, ChB from the Respiratory Biomedical Research Unit, Royal Brompton and Harefield National Health Service Foundation Trust, London; N. Gerard McElvaney, MD from the Royal College of Surgeons and Beaumont Hospital, both in Dublin; Elizabeth Tullis, MD from St. Michael's Hospital, University of Toronto; Scott C. Bell, MB, BS, MD from the Department of Thoracic Medicine, Prince Charles Hospital and Queensland Children's Medical Research Institute, University of Queensland in Brisbane, Australia; Pavel Dřevínek, MD from the Department of Pediatrics, 2nd Medical School, Charles University, Prague, Czech Republic; Matthias Griese, MD from Dr von Haunersches Kinderspital, University of Munich, Munich, Germany; Edward F. McKone, MD, from St. Vincent's University Hospital in Dublin; Claire E. Wainwright, MD, MB, BS from St. Vincent's University Hospital in Dublin and the Queensland Children's Medical Research Institute, University of Queensland in Brisbane, Australia; Michael W. Konstan, MD from Case Western Reserve University School of Medicine, Rainbow Babies and Children's Hospital, Cleveland; Richard Moss, MD from Stanford University School of Medicine, Stanford, CA; Felix Ratjen, MD, PhD from the University of Toronto Department of Pediatrics and Hospital for Sick Children in Toronto; Isabelle Sermet-Gaudelus, MD, PhD from the Centre d'Investigation Clinique–Hôpital Necker, Paris; Steven M. Rowe, MD, MSPH from the University of Alabama at Birmingham, Birmingham; Qunming Dong, PhD, Sally Rodriguez, PhD, Karl Yen, MD and Claudia Ordoñez, MD from Vertex Pharmaceuticals, Cambridge, MA; and J. Stuart Elborn, MD from the Centre for Infection and Immunity, Queens University Belfast, Belfast, United Kingdom.

About Seattle Children's Research Institute

At the forefront of pediatric medical research, Seattle Children's Research Institute is setting new standards in pediatric care and finding new cures for childhood diseases. Internationally recognized scientists and physicians at the Research Institute are advancing new discoveries in cancer, genetics, immunology, pathology, infectious disease, injury prevention and bioethics. With Seattle Children's Hospital and Seattle Children's Hospital Foundation, the Research Institute brings together the best minds in pediatric research to provide patients with the best care possible. Children's serves as the primary teaching, clinical and research site for the Department of Pediatrics at the University of Washington School of Medicine, which consistently ranks as one of the best pediatric departments in the country. For more information, visit http://www.seattlechildrens.org/research.

About UW Medicine

UW Medicine trains health professionals and medical scientists, conducts research to improve health and prevent disease worldwide, and provides primary and specialty care to patients throughout Seattle/King County and the WWAMI (Washington, Wyoming, Alaska, Montana and Idaho) region. UW Medicine includes: Harborview Medical Center, UW Medical Center, Northwest Hospital & Medical Center, Valley Medical Center, UW Neighborhood Clinics, UW School of Medicine, UW Physicians, and Airlift Northwest. UW Medicine also shares in the ownership and governance of the Seattle Cancer Care Alliance with Seattle Children's Hospital and Fred Hutchinson Cancer Research Center and shares in ownership of Children's University Medical Group with Seattle Children's Hospital. UW Medicine has major academic and service affiliations with Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, the Veteran's Affairs Puget Sound Health Care System in Seattle, and the VA Hospital in Boise, Idaho. The UW School of Medicine has been ranked #1 in the nation in primary-care training for the past 18 years by US News & World Report. It is the top public institution for receipt of biomedical research funding from the National Institutes of Health (NIH) and second among all institutions for NIH funding, public and private. UW Medicine's 2,000 full-time faculty and nearly 5,000 volunteer and part-time faculty include four Nobel Laureates, 33 members of the National Academy of Sciences, and 33 members of the Institute of Medicine. For more information, visit UW Medicine.org. Follow us on Twitter - @UWMedicineNews

Media Contacts:
Louise Maxwell
Seattle Children's Research Institute
Email: louise.maxwell@seattlechildrens.org
Phone: 206-987-5210
Clare Hagerty
UW Medicine
Email: clareh@u.washington.edu
Phone: 206-685-1323

Louise Maxwell | EurekAlert!
Further information:
http://www.seattlechildrens.org

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Physicists discover mechanism behind granular capillary effect

24.05.2017 | Physics and Astronomy

Measured for the first time: Direction of light waves changed by quantum effect

24.05.2017 | Physics and Astronomy

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>